Mihaela S Stefan1, Patrick Eckert2, Bogdan Tiru3, Jennifer Friderici4, Peter K Lindenauer1, Jay S Steingrub3. 1. a Center for Quality of Care Research, Department of Medicine , Baystate Medical Center , Springfield , MA , USA. 2. b Department of Pulmonary and Critical Care Medicine , Christiana Care Health System , Newark , DE , USA. 3. c Division of Pulmonary and Critical Care , Baystate Medical Center , Springfield , MA , USA. 4. d Epidemiology & Biostatistics , Baystate Medical Center , Springfield , MA , USA.
Abstract
OBJECTIVE: To examine the use of high flow nasal cannula oxygen therapy (HFNC) between 2008 and 2014 in patients 18 years or older at a community teaching hospital. METHODS: Yearly utilization rates of HFNC, noninvasive ventilation (NIV) and invasive mechanical ventilation (IMV) were calculated among admissions with a set of cardiopulmonary diagnoses (heart failure, COPD, asthma or pneumonia). RESULTS: Among the 41,711 admissions with at least one of the above cardiopulmonary condition, HFNC was utilized in 1,128 or 27.0/1000; NIV was used in an average of 169/1000 and IMV in 231/1000. HFNC was accompanied by IMV or NIV 71.3% of the time. From 2008 to 2014 HFNC utilization increased an average of 17.5% annually; NIV increased by 10.2% annually while IMV's utilization increased by 1.6% annually. The highest rate of change in HFNC use was among admissions with pneumonia and those with COPD. CONCLUSION: HFNC utilization increased steadily over a 7-year period at our hospital. Frequently, HFNC therapy was used in combination with other ventilatory modes to support patients' respiration. Similar with other technologies in healthcare, the uptake of HFNC has preceded the evidence from robust clinical trials.
OBJECTIVE: To examine the use of high flow nasal cannula oxygen therapy (HFNC) between 2008 and 2014 in patients 18 years or older at a community teaching hospital. METHODS: Yearly utilization rates of HFNC, noninvasive ventilation (NIV) and invasive mechanical ventilation (IMV) were calculated among admissions with a set of cardiopulmonary diagnoses (heart failure, COPD, asthma or pneumonia). RESULTS: Among the 41,711 admissions with at least one of the above cardiopulmonary condition, HFNC was utilized in 1,128 or 27.0/1000; NIV was used in an average of 169/1000 and IMV in 231/1000. HFNC was accompanied by IMV or NIV 71.3% of the time. From 2008 to 2014 HFNC utilization increased an average of 17.5% annually; NIV increased by 10.2% annually while IMV's utilization increased by 1.6% annually. The highest rate of change in HFNC use was among admissions with pneumonia and those with COPD. CONCLUSION: HFNC utilization increased steadily over a 7-year period at our hospital. Frequently, HFNC therapy was used in combination with other ventilatory modes to support patients' respiration. Similar with other technologies in healthcare, the uptake of HFNC has preceded the evidence from robust clinical trials.
Entities:
Keywords:
High flow nasal cannula oxygen; mechanical ventilation; respiratory failure
Authors: Benjamin Sztrymf; Jonathan Messika; Thomas Mayot; Hugo Lenglet; Didier Dreyfuss; Jean-Damien Ricard Journal: J Crit Care Date: 2011-09-29 Impact factor: 3.425
Authors: Gonzalo Hernández; Concepción Vaquero; Laura Colinas; Rafael Cuena; Paloma González; Alfonso Canabal; Susana Sanchez; Maria Luisa Rodriguez; Ana Villasclaras; Rafael Fernández Journal: JAMA Date: 2016-10-18 Impact factor: 56.272
Authors: Reiko Asano; Stephen C Mathai; Peter S Macdonald; Phillip J Newton; David C Currow; Jane Phillips; Wing-Fai Yeung; Patricia M Davidson Journal: Heart Fail Rev Date: 2020-03 Impact factor: 4.214